QQuatre Lab
Quatre Lab (legal name Quality Advanced Therapies Research, S.L.) is a Spanish contract research organization providing GMP-compliant quality control, analytical method development and validation, potency/purity/safety testing and cell banking for Advanced Therapy Medicinal Products (ATMPs) such as cell and gene therapies. It was created in late 2021 by Valencia-based Columbus Venture Partners through its Life Sciences Fund III with roughly €5M, following the same team's Viralgen playbook, and obtained AEMPS accreditation as a GMP pharmaceutical laboratory in 2024. It is headquartered in Donostia-San Sebastián (Miramón / Gipuzkoa Science and Technology Park).
SectorsBiotech, Advanced Therapies (ATMPs), CRO / Life Sciences Services, Quality Control & Testing, Cell and Gene Therapy
Start-up MapHealthtech & Bio › Biologics manufacturing & CDMO
Founders
P
Patricia Muñoz Garrido
Founding Managing Director / CEO
Global models 4
RResilience
United States · resilience.com ↗
Venture-backed contract manufacturer offering GMP manufacturing plus analytical and quality-control testing services to cell and gene therapy developers on a fee-for-service basis.
$2BComparable
EElevateBio
United States · elevate.bio ↗
Its BaseCamp unit sells GMP process development, analytical testing and manufacturing services for cell and gene therapies to biotech clients.
$1.2BComparable
CCenter for Breakthrough Medicines
United States · www.cbm.com ↗
Cell and gene therapy contract organisation offering GMP testing, analytical development, cell banking and manufacturing services to therapy developers.
$1.1BComparable
CCellares
United States · www.cellares.com ↗
Provides cell therapy manufacturing and automated GMP quality-control release testing (Cell Q) as a service for ATMP developers.
$355MComparable
In the same niche 8 others
See all in the Start-ups Map →Notes: Most funded first
Investors 2
Open as list →Funding rounds 1
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2023-06-01 | Seed | approximately €5M |
Lead not disclosed
+2 more
|
News
No coverage on record yet.







